Diagnostic Tools for Sarcopenia: Can We Get Less Expensive and Accurate Methods?
In 2018, EWGSOP made a revision regarding sarcopenia, as well as the diagnostic test and cut-off value (EWGSOP2). EWGSOP2 recommends using self-questionnaire, known as SARC-F as sarcopenia screening, especially in community-dwelling elderly. SARC-F consisted of 5 questions regarding patient’s perception of his or her limitations in strength, walking ability, rising from a chair, stair climbing and experiences with falls. This is more feasible to be done in countries without advanced muscle mass measurement tools. Several parameters in sarcopenia are muscle strength, muscle quantity, and physical performance. In muscle strength, measuring grip strength can be done as predictor for patients’ outcomes, such as hospitalization and quality of life. For muscle quantity, the gold standards are Magnetic resonance imaging (MRI) and computed tomography (CT). However, since both are expensive, and the cut-off points have not been defined yet, DXA and Bioelectrical impedance analysis (BIA) can be a substitute. Current evidence showed that DXA still does not give consistent results and not yet portable for the use in the community. On the other hand, BIA measure muscle mass using the whole-body electrical conductivity and less expensive than the other tools, thus can be used in the community setting. However, there is no specific cut-off for BIA especially in elderly. For physical performance, several tests can be done, such as gait speed and Timed-Up and Go test (TUG).
Cruz-Jentoft A, Bahat G, Bauer J, et al. Sarcopenia: revised European consensus on definition and diagnosis. Age and Ageing. 2019;48:16-31.
Chen LK, Lee WJ, Peng LN. Recent Advances in Sarcopenia Research in Asia: 2016 Update From the Asian Working Group for Sarcopenia. JAMDA. 2016;17(767);e1-767.e7.
- There are currently no refbacks.